Petros Pharmaceuticals, Inc. PTPI

PTPI Company Overview

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a U.S.-based pharmaceutical company focused on men’s health, with primary activities centered on prescription therapeutics, digital health integration, and consumer healthcare products. The company is best known for commercializing STENDRA (avanafil), a phosphodiesterase type 5 (PDE5) inhibitor indicated for erectile dysfunction in adult men. Petros has operated in the specialty pharmaceutical and men’s wellness sectors, combining branded prescription products with telehealth-oriented distribution and patient access initiatives. Its revenue historically has been driven by prescription sales, licensing arrangements, royalties, and commercialization partnerships tied to men’s health therapeutics.

The company traces its roots to the men’s health assets formerly associated with Metuchen Pharmaceuticals and Neurotrope, Inc., which later restructured and rebranded as Petros Pharmaceuticals. Over time, Petros expanded beyond traditional pharmaceutical distribution by integrating digital healthcare strategies intended to improve access to erectile dysfunction treatment through online prescribing and fulfillment models. The company’s positioning has emphasized brand recognition around STENDRA, regulatory approvals, intellectual property related to avanafil formulations, and efforts to participate in the growing direct-to-consumer men’s health market.